Copy to clipboard 
Amplitude Surgical reported fiscal year 2Q21 orthopedic sales of €27.9 million ($34.1 million), +14.7% vs. 2Q20.
Through its first two quarters, the company’s joint replacement sales are just above flat compared to the prior year, but its Novastep foot and ankle line continues to show steady growth. Foot and ankle sales, particularly in the U.S. market, helped sustain Amplitude throughout the pandemic. The Novastep line accounted for more than 17% of Amplitude’s Q2 sales, an all-time high for the company.
Amplitude CEO Olivier Jallabert said, “Knee and hip activity continues to be negatively affected by the public health situation associated with the COVID-19 pandemic, with further health restrictions and canceled operations as well as the reduced availability of operating rooms and medical staff.”
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 2Q21 | 2Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $28.2 | $25.5 | $2.8 | 10.8% |
| Knees | $15.4 | $14.1 | $1.2 | 8.8% |
| Hips | $12.9 | $11.3 | $1.5 | 13.3% |
| Trauma | $5.8 | $4.2 | $1.6 | 38.6% |
| Total | $34.1 | $29.7 | $4.4 | 14.7% |
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $49.0 | $48.9 | $0.1 | 0.3% |
| Knees | $26.8 | $27.2 | ($0.4) | (1.6%) |
| Hips | $22.2 | $21.6 | $0.6 | 2.6% |
| Trauma | $9.7 | $7.1 | $2.5 | 35.5% |
| Total | $58.7 | $56.0 | $2.7 | 4.8% |
Orthopedic Sales by Geography
| 2Q21 | 2Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $22.3 | $18.9 | $3.4 | 17.9% |
| International | $11.8 | $10.8 | $1.0 | 9.1% |
| Subsidiaries | $9.2 | $8.5 | $0.7 | 8.8% |
| Distributors | $2.6 | $2.3 | $0.2 | 10.3% |
| Total | $34.1 | $29.7 | $4.4 | 14.7% |
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $37.2 | $36.1 | $1.1 | 3% |
| International | $21.5 | $19.9 | $1.6 | 8% |
| Subsidiaries | $16.9 | $15.2 | $1.7 | 11% |
| Distributors | $4.6 | $4.7 | ($0.1) | (1.7%) |
| Total | $58.7 | $56.0 | $2.7 | 4.8% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Amplitude Surgical reported fiscal year 2Q21 orthopedic sales of €27.9 million ($34.1 million), +14.7% vs. 2Q20.
Through its first two quarters, the company's joint replacement sales are just above flat compared to the prior year, but its Novastep foot and ankle line continues to show steady growth. Foot and ankle sales, particularly in the...
Amplitude Surgical reported fiscal year 2Q21 orthopedic sales of €27.9 million ($34.1 million), +14.7% vs. 2Q20.
Through its first two quarters, the company’s joint replacement sales are just above flat compared to the prior year, but its Novastep foot and ankle line continues to show steady growth. Foot and ankle sales, particularly in the U.S. market, helped sustain Amplitude throughout the pandemic. The Novastep line accounted for more than 17% of Amplitude’s Q2 sales, an all-time high for the company.
Amplitude CEO Olivier Jallabert said, “Knee and hip activity continues to be negatively affected by the public health situation associated with the COVID-19 pandemic, with further health restrictions and canceled operations as well as the reduced availability of operating rooms and medical staff.”
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 2Q21 | 2Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $28.2 | $25.5 | $2.8 | 10.8% |
| Knees | $15.4 | $14.1 | $1.2 | 8.8% |
| Hips | $12.9 | $11.3 | $1.5 | 13.3% |
| Trauma | $5.8 | $4.2 | $1.6 | 38.6% |
| Total | $34.1 | $29.7 | $4.4 | 14.7% |
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $49.0 | $48.9 | $0.1 | 0.3% |
| Knees | $26.8 | $27.2 | ($0.4) | (1.6%) |
| Hips | $22.2 | $21.6 | $0.6 | 2.6% |
| Trauma | $9.7 | $7.1 | $2.5 | 35.5% |
| Total | $58.7 | $56.0 | $2.7 | 4.8% |
Orthopedic Sales by Geography
| 2Q21 | 2Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $22.3 | $18.9 | $3.4 | 17.9% |
| International | $11.8 | $10.8 | $1.0 | 9.1% |
| Subsidiaries | $9.2 | $8.5 | $0.7 | 8.8% |
| Distributors | $2.6 | $2.3 | $0.2 | 10.3% |
| Total | $34.1 | $29.7 | $4.4 | 14.7% |
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $37.2 | $36.1 | $1.1 | 3% |
| International | $21.5 | $19.9 | $1.6 | 8% |
| Subsidiaries | $16.9 | $15.2 | $1.7 | 11% |
| Distributors | $4.6 | $4.7 | ($0.1) | (1.7%) |
| Total | $58.7 | $56.0 | $2.7 | 4.8% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
